Natera (NTRA) | Financial Analysis & Statements
Natera Inc. Large-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
665.5M
Gross Profit
445.4M
66.93%
Operating Income
-22.8M
-3.42%
Net Income
47.3M
7.10%
Balance Sheet Metrics
Total Assets
2.4B
Total Liabilities
685.9M
Shareholders Equity
1.7B
Debt to Equity
0.40
Cash Flow Metrics
Operating Cash Flow
74.1M
Free Cash Flow
17.3M
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Natera Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 2.3B | 1.7B | 1.1B | 820.2M | 625.5M |
| Cost of Goods Sold | 812.9M | 673.8M | 589.8M | 456.3M | 318.4M |
| Gross Profit | 1.5B | 1.0B | 492.7M | 364.0M | 307.1M |
| Gross Margin % | 64.7% | 60.3% | 45.5% | 44.4% | 49.1% |
| Operating Expenses | |||||
| Research & Development | 624.1M | 404.1M | 320.7M | 316.4M | 264.2M |
| Selling, General & Administrative | 1.2B | 841.3M | 618.3M | 588.6M | 511.0M |
| Other Operating Expenses | - | - | - | - | - |
| Total Operating Expenses | 1.8B | 1.2B | 939.0M | 905.0M | 775.2M |
| Operating Income | -309.9M | -222.3M | -446.2M | -541.0M | -468.2M |
| Operating Margin % | -13.4% | -13.1% | -41.2% | -66.0% | -74.8% |
| Non-Operating Items | |||||
| Interest Income | 45.9M | 43.2M | 24.4M | 3.5M | 5.4M |
| Interest Expense | 4.1M | 10.7M | 12.6M | 9.3M | 8.3M |
| Other Non-Operating Income | - | - | - | - | 5.4M |
| Pre-tax Income | -268.1M | -189.7M | -434.5M | -546.8M | -471.1M |
| Income Tax | -59.9M | 695.0K | 271.0K | 978.0K | 618.0K |
| Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Income | -208.2M | -190.4M | -434.8M | -547.8M | -471.7M |
| Net Margin % | -9.0% | -11.2% | -40.2% | -66.8% | -75.4% |
| Key Metrics | |||||
| EBITDA | -220.5M | -148.1M | -397.8M | -520.8M | -451.5M |
| EPS (Basic) | - | $-1.53 | $-3.78 | $-5.57 | $-5.21 |
| EPS (Diluted) | - | $-1.53 | $-3.78 | $-5.57 | $-5.21 |
| Basic Shares Outstanding | - | 124718000 | 114997000 | 98408000 | 90558000 |
| Diluted Shares Outstanding | - | 124718000 | 114997000 | 98408000 | 90558000 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Natera Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 1.1B | 945.6M | 642.1M | 466.1M | 84.4M |
| Short-term Investments | 0 | 22.7M | 236.9M | 432.3M | 829.9M |
| Accounts Receivable | 296.5M | 314.2M | 278.3M | 244.4M | 122.1M |
| Inventory | 68.4M | 44.7M | 40.8M | 35.4M | 26.9M |
| Other Current Assets | 55.8M | 48.6M | 60.5M | 33.6M | 29.6M |
| Total Current Assets | 1.5B | 1.4B | 1.3B | 1.2B | 1.1B |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 108.5M | 86.1M | 56.5M | 71.9M | 59.0M |
| Goodwill | 655.9M | - | - | - | - |
| Intangible Assets | 373.7M | - | - | - | - |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 36.9M | 36.7M | 15.4M | 18.3M | 18.8M |
| Total Non-Current Assets | 901.4M | 284.9M | 183.2M | 182.7M | 143.3M |
| Total Assets | 2.4B | 1.7B | 1.4B | 1.4B | 1.2B |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 33.2M | 34.9M | 15.0M | 31.1M | 27.2M |
| Short-term Debt | 95.9M | 90.5M | 92.0M | 88.0M | 55.8M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | - | - | - | - | - |
| Total Current Liabilities | 441.2M | 344.0M | 307.3M | 310.5M | 219.0M |
| Non-Current Liabilities | |||||
| Long-term Debt | 118.5M | 96.6M | 350.0M | 358.2M | 341.4M |
| Deferred Tax Liabilities | 701.0K | - | - | - | - |
| Other Non-Current Liabilities | 11.7M | - | - | - | 1.5M |
| Total Non-Current Liabilities | 244.7M | 121.3M | 369.1M | 378.2M | 364.2M |
| Total Liabilities | 685.9M | 465.3M | 676.4M | 688.7M | 583.2M |
| Equity | |||||
| Common Stock | 14.0K | 12.0K | 11.0K | 11.0K | 10.0K |
| Retained Earnings | -2.8B | -2.6B | -2.4B | -1.9B | -1.4B |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 1.7B | 1.2B | 765.3M | 705.7M | 653.3M |
| Key Metrics | |||||
| Total Debt | 214.4M | 187.1M | 442.0M | 446.2M | 397.2M |
| Working Capital | 1.1B | 1.0B | 951.3M | 901.3M | 874.2M |
Balance Sheet Composition
Natera Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -208.2M | -190.4M | -434.8M | -547.8M | -471.7M |
| Depreciation & Amortization | 43.5M | 31.0M | 24.1M | 16.7M | 11.3M |
| Stock-Based Compensation | 354.4M | 274.4M | 191.8M | 152.4M | 115.2M |
| Working Capital Changes | -72.9M | -42.6M | -53.8M | -132.7M | -85.7M |
| Operating Cash Flow | 135.5M | 91.1M | -254.2M | -486.8M | -383.1M |
| Investing Activities | |||||
| Capital Expenditures | -106.2M | -66.4M | -39.2M | -47.7M | -41.0M |
| Acquisitions | -16.0M | - | - | - | 0 |
| Investment Purchases | 0 | -124.7M | -98.3M | -86.9M | -876.1M |
| Investment Sales | 23.0M | 339.2M | 306.0M | 465.0M | 720.5M |
| Investing Cash Flow | -99.2M | 148.1M | 168.5M | 330.3M | -205.2M |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | - | 0 | - | 0 | 0 |
| Debt Repayment | 0 | -82.0K | - | 0 | 0 |
| Financing Cash Flow | -112.0K | -82.0K | 235.4M | 463.2M | 550.8M |
| Free Cash Flow | 76.1M | 58.7M | -286.2M | -479.2M | -376.3M |
| Net Change in Cash | 36.2M | 239.1M | 149.7M | 306.8M | -37.4M |
Cash Flow Trend
Natera Key Financial Ratios
Valuation Ratios
Forward P/E
-272.56
Price to Book
15.75
Price to Sales
11.86
PEG Ratio
-272.56
Profitability Ratios
Profit Margin
-9.03%
Operating Margin
-3.42%
Return on Equity
-14.32%
Return on Assets
-9.54%
Financial Health
Current Ratio
3.39
Debt to Equity
12.52
Beta
1.68
Per Share Data
EPS (TTM)
$-1.52
Book Value per Share
$12.26
Revenue per Share
$16.87
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| NTRA | 27.4B | - | 15.75 | -14.32% | -9.03% | 12.52 |
| Thermo Fisher | 174.6B | 25.84 | 3.31 | 13.52% | 15.15% | 82.91 |
| Danaher | 126.4B | 34.61 | 2.40 | 7.08% | 14.89% | 37.17 |
| Idexx Laboratories | 44.7B | 42.92 | 27.85 | 66.20% | 24.62% | 60.83 |
| Agilent Technologies | 32.7B | 25.67 | 4.76 | 19.95% | 18.26% | 51.39 |
| Waters | 30.5B | 28.90 | 7.24 | 29.28% | 20.30% | 60.28 |
Financial data is updated regularly. All figures are in the company's reporting currency.






